Team Vivo

Important change from Blue Cross Blue Shield of Michigan (BCBSM) that will affect some of our patients receiving Entyvio® IV.

Beginning January 1, 2026, BCBSM will continue to cover Entyvio® IV for the initial loading doses given in a healthcare setting. After the loading phase, most members will be required to transition to the self-injection (subcutaneous or “SC”) form through the pharmacy benefit. Exceptions may be approved for patients who are not able to self-administer the medication.

BCBSM has stated that this change is based on cost-management goals and its interpretation of national treatment guidelines, which describe Entyvio® IV and Entyvio® SC as therapeutically equivalent. While both forms contain the same medication, the experience of care is not the same.

At Vivo Infusion, we know that many patients have achieved stability on Entyvio® IV through consistent, professionally supervised infusions. This change may cause concern for patients who depend on that monitoring and relationship-based care. Our role is to support them with compassion, expertise, and clear information.

Why This Matters

Infusion’s commitment has always been to patient-centered, physician-directed care. This policy change underscores the importance of our mission: to ensure patients have access to the treatment that best supports their individual medical needs. Decisions about care should always remain between patients and their physicians, not dictated by insurance policy.

How Vivo Is Supporting Patients and Staff

To help patients and team members through this transition, we have developed several educational and support tools.

These resources are designed to ensure that both staff and patients have clear, consistent information and access to support.

Your Role

Every patient conversation matters.

You are the trusted connection between Vivo Infusion and our patients, and your guidance will help them feel supported and informed. Please remind patients that:

  • BCBSM’s decision is an insurance policy change, not a medical one.
  • Their treatment plan should always be decided between them and their physician.
  • Vivo Infusion is here to help them understand their options, navigate exception requests, and advocate for continued access to safe, effective care.

Thank you!

Thank you for continuing to provide exceptional care and professionalism during this transition. Your compassion and expertise make a difference every day. If you have questions or need assistance, please reach out to your manager or the clinical leadership team.

Together, we will continue to stand beside our patients and physicians, ensuring that care decisions remain where they belong—between the patient and their doctor.